PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL AS FIRST-LINE CHEMOTHERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION

被引：0
|
作者：
Tamiya, Akihiro [1 ]
Tamiya, Motohiro [2 ]
Yamadori, Tadahiro [2 ]
Yasue, Tomomi [3 ]
Nakao, Keiko [1 ]
Shiroyama, Takayuki [2 ]
Asami, Kazuhiro [1 ]
Morishita, Naoko [2 ]
Suzuki, Hidekazu [2 ]
Okamoto, Norio [2 ]
Okishio, Kyoichi [4 ]
Kawaguchi, Tomoya [1 ]
Hirashima, Tomonori [2 ]
Atagi, Shinji [4 ]
机构：
[1] Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
[2] Osaka Prefectural Hosp Org, Osaka Prefectural Med Ctr Resp & Allerg Dis, Osaka, Japan
[3] Osaka Prefectural Hosp Org, Osaka Prefectural Med Ctr Resp & Allerg Dis, Clin Lab, Osaka, Japan
[4] Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
non-small cell lung cancer; Bevacizumab; VEGF; malignant pleural effusion;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.10-009
引用
收藏
页码：S1159 / S1160
页数：2
相关论文
共 50 条
  • [1] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kazuhiro Kitamura
    Kaoru Kubota
    Masahiro Ando
    Satoshi Takahashi
    Nobuhiko Nishijima
    Teppei Sugano
    Masaru Toyokawa
    Koji Miwa
    Seiji Kosaihira
    Rintaro Noro
    Yuji Minegishi
    Masahiro Seike
    Akinobu Yoshimura
    Akihiko Gemma
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 457 - 461
  • [2] Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
    Kitamura, Kazuhiro
    Kubota, Kaoru
    Ando, Masahiro
    Takahashi, Satoshi
    Nishijima, Nobuhiko
    Sugano, Teppei
    Toyokawa, Masaru
    Miwa, Koji
    Kosaihira, Seiji
    Noro, Rintaro
    Minegishi, Yuji
    Seike, Masahiro
    Yoshimura, Akinobu
    Gemma, Akihiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (02) : 457 - 461
  • [3] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
  • [4] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous non-small cell lung cancer
    Ciuleanu, T.
    Tsai, C. -M.
    Tsao, C. -J.
    Milanowski, J.
    Amoroso, D.
    Heo, D. S.
    Groen, H. J. M.
    Szczesna, A.
    Chung, C. -Y.
    Chao, T. -Y.
    Middleton, G.
    Zeaiter, A.
    Klingelschmitt, G.
    Klughammer, B.
    Thatcher, N.
    LUNG CANCER, 2013, 82 (02) : 276 - 281
  • [5] Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Yamadori, Tadahiro
    Nakao, Keiko
    Asami, Kazuhiro
    Yasue, Tomomi
    Otsuka, Tomoyuki
    Shiroyama, Takayuki
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Atagi, Shinji
    Kawase, Ichiro
    Hirashima, Tomonori
    MEDICAL ONCOLOGY, 2013, 30 (03)
  • [6] A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion
    Wu Di
    Cong Yue
    Zhang Ziran
    Zhang Jie
    Nie Jun
    Dai Ling
    Hu Weiheng
    Chen Xiaoling
    Ma Xiangjuan
    Tian Guangming
    Han Jindi
    Han Sen
    Wang Yang
    Long Jieran
    Fang Jian
    FUTURE ONCOLOGY, 2022, 18 (06) : 669 - 677
  • [7] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab‐paclitaxel for non‐squamous non‐small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Hidekazu Suzuki
    Yoshihiko Taniguchi
    Kanako Katayama
    Shojiro Minomo
    Keiko Nakao
    Naoko Takeuchi
    Yoshinobu Matsuda
    Yujiro Naito
    Takayuki Shiroyama
    Norio Okamoto
    Kyoichi Okishio
    Toru Kumagai
    Shinji Atagi
    Fumio Imamura
    Tomonori Hirashima
    Investigational New Drugs, 2021, 39 : 1106 - 1112
  • [8] Phase2 study of bevacizumab with carboplatin–paclitaxel for non-small cell lung cancer with malignant pleural effusion
    Motohiro Tamiya
    Akihiro Tamiya
    Tadahiro Yamadori
    Keiko Nakao
    Kazuhiro Asami
    Tomomi Yasue
    Tomoyuki Otsuka
    Takayuki Shiroyama
    Naoko Morishita
    Hidekazu Suzuki
    Norio Okamoto
    Kyoichi Okishio
    Tomoya Kawaguchi
    Shinji Atagi
    Ichiro Kawase
    Tomonori Hirashima
    Medical Oncology, 2013, 30
  • [9] Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer
    Kubota, Tetsuya
    Okano, Yoshio
    Sakai, Mizu
    Takaoka, Masato
    Tsukuda, Tsukie
    Anabuki, Kazuki
    Kawase, Shigeo
    Miyamoto, Shintaro
    Ohnishi, Hiroshi
    Hatakeyama, Nobuo
    Machida, Hisanori
    Urata, Tomoyuki
    Yamamoto, Akira
    Ogushi, Fumitaka
    Yokoyama, Akihito
    ANTICANCER RESEARCH, 2016, 36 (01) : 307 - 312
  • [10] Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
    Niho, Seiji
    Kunitoh, Hideo
    Nokihara, Hiroshi
    Horai, Takeshi
    Ichinose, Yukito
    Hida, Toyoaki
    Yamamoto, Nobuyuki
    Kawahara, Masaaki
    Shinkai, Tetsu
    Nakagawa, Kazuhiko
    Matsui, Kaoru
    Negoro, Shunichi
    Yokoyama, Akira
    Kudoh, Shinzoh
    Kiura, Katsuyuki
    Mori, Kiyoshi
    Okamoto, Hiroaki
    Sakai, Hiroshi
    Takeda, Koji
    Yokota, Soichiro
    Saijo, Nagahiro
    Fukuoka, Masahiro
    LUNG CANCER, 2012, 76 (03) : 362 - 367
12345